Jazz Pharmaceuticals Q2 2026 earnings preview

Jazz Pharmaceuticals (JAZZ) will report Q2 2026 earnings on August 3rd after market close. Consensus estimates project EPS of $6.18, up 174.9% year-over-year, and revenue of $1.11 billion, a 5.7% increase. Historically, the company has beaten both EPS and revenue estimates in 75% of quarters over the past two years.

Jazz Pharmaceuticals (JAZZ) is scheduled to announce Q2 earnings results on Monday, August 3rd, after market close. The consensus EPS estimate is $6.18 (+174.9% Y/Y), and the consensus revenue estimate is $1.11B (+5.7% Y/Y). Over the last 2 years, JAZZ has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time. Over t...